Journal of Applied Physiology Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


J Appl Physiol 89: 1213-1223, 2000;
8750-7587/00 $5.00
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (12)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Clouse, W. D.
Right arrow Articles by Miller, V. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Clouse, W. D.
Right arrow Articles by Miller, V. M.
Vol. 89, Issue 3, 1213-1223, September 2000

Effects of transdermal nicotine treatment on structure and function of coronary artery bypass grafts

William D. Clouse1, Hiroki Yamaguchi1, Michael R. Phillips1, Richard D. Hurt2, Lorraine A. Fitzpatrick5, Thomas P. Moyer3, Charles Rowland6, Hartzell V. Schaff1, and Virginia M. Miller1,4

1 Division of Cardiovascular Surgery, Department of Surgery, 2 Nicotine Research Center, Department of Internal Medicine, 3 Department of Laboratory Medicine, 4 Department of Physiology and Biophysics, 5 Division of Endocrinology, Department of Internal Medicine, and 6 Section of Biostatistics, Mayo Clinic and Foundation, Rochester, Minnesota 55905

Smoking is a major risk factor for failure of coronary artery bypass grafts (CABG). Experiments were designed to determine effects of transdermal nicotine, independent of smoking, on structure and function of CABG. Saphenous veins were placed as CABG in untreated dogs (control) or in dogs treated with transdermal nicotine (one 11-mg or two 22-mg patches/day) for 5 wk. Serum nicotine and plasma nitric oxide were measured. Grafts were removed and prepared for organ chamber studies and histology. Serum nicotine averaged 12.1 and 118.7 ng/ml in the 11 mg/day and 44 mg/day groups, respectively. Plasma nitric oxide was higher in dogs treated with 11 mg/day doses compared with controls. In organ chamber studies, endothelium-dependent relaxations to thrombin and A-23187 and endothelium-independent relaxations to nitric oxide were greatest in grafts from dogs treated with 11 mg/day doses. Intimal thickness of the grafts were similar among groups. However, staining for bone sialoprotein was increased in the media of grafts from the 11 mg/day treatment group. These data suggest that transdermal nicotine in doses comparable and double to those used for conventional smoking cessation treatment in humans does not adversely affect early patency of canine CABG up to 4 wk postoperatively. Transdermal nicotine, however, may increase production of and response to nitric oxide in bypass grafts.

endothelium; nitric oxide; saphenous vein; smoking cessation; vascular smooth muscle


This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
D. Xiao, X. Huang, J. Lawrence, S. Yang, and L. Zhang
Fetal and Neonatal Nicotine Exposure Differentially Regulates Vascular Contractility in Adult Male and Female Offspring
J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 654 - 661.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
E. Rzewuska-Lech, M. Jayachandran, L. A. Fitzpatrick, and V. M. Miller
Differential effects of 17{beta}-estradiol and raloxifene on VSMC phenotype and expression of osteoblast-associated proteins
Am J Physiol Endocrinol Metab, July 1, 2005; 289(1): E105 - E112.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. A. Ambrose and R. S. Barua
The pathophysiology of cigarette smoking and cardiovascular disease: An update
J. Am. Coll. Cardiol., May 19, 2004; 43(10): 1731 - 1737.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
T. P. Moyer, J. R. Charlson, R. J. Enger, L. C. Dale, J. O. Ebbert, D. R. Schroeder, and R. D. Hurt
Simultaneous Analysis of Nicotine, Nicotine Metabolites, and Tobacco Alkaloids in Serum or Urine by Tandem Mass Spectrometry, with Clinically Relevant Metabolic Profiles
Clin. Chem., September 1, 2002; 48(9): 1460 - 1471.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
V. M. Miller, W. D. Clouse, B. H. Tonnessen, U. S. Boston, S. R. Severson, S. Bonde, K. S. Rud, and R. D. Hurt
Time and dose effect of transdermal nicotine on endothelial function
Am J Physiol Heart Circ Physiol, October 1, 2000; 279(4): H1913 - H1921.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online